Related Experiment Video

Updated: Aug 8, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Tyrphostins and other tyrosine kinase inhibitors

Alexander Levitzki1, Eyal Mishani

  • 1The Silberman Institute for Life Sciences, Department of Biological Chemistry, The Hebrew University, Givat Ram Campus, Jerusalem 91904, Israel. levitzki@vms.huji.ac.il

Annual Review of Biochemistry
|June 8, 2006
PubMed

Insights

Targeted tyrosine kinase inhibitors offer a less toxic cancer therapy approach. These inhibitors can also treat nonmalignant conditions by blocking specific protein tyrosine kinases (PTKs).

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Tyrosine phosphorylation inhibitors have revolutionized cancer treatment.
  • Protein tyrosine kinases (PTKs) are crucial in cellular signaling.
  • Existing chemotherapy agents often exhibit significant toxicity.

Purpose of the Study:

  • To review principles for developing specific protein tyrosine kinase (PTK) inhibitors.
  • To explore targeted, non-toxic signal transduction inhibitors.
  • To discuss the therapeutic potential of PTK inhibitors beyond cancer treatment.

Main Methods:

  • Review of scientific literature on PTK inhibitors.
  • Discussion of ATP-competitive versus substrate-competitive inhibition strategies.
  • Analysis of combining PTK inhibitors with other signal transduction modulators.

Main Results:

  • Development of small molecules targeting specific PTKs with reduced toxicity is feasible.
  • Substrate-competitive inhibitors present an alternative to ATP-competitive PTK inhibitors.
  • Combination therapies can enhance apoptosis in cancer cells.

Conclusions:

  • PTK inhibitors represent a promising therapeutic strategy for cancer.
  • PTK inhibitors have potential applications in treating nonmalignant conditions like immune disorders and restenosis.
  • Targeted inhibition of PTKs offers a path towards more precise and less toxic medical interventions.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...